A 5-Year Review of Invasive Fungal Infection at an Academic Medical Center.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • Additional Information
    • Source:
      Publisher: Frontiers Media SA Country of Publication: Switzerland NLM ID: 101585359 Publication Model: eCollection Cited Medium: Internet ISSN: 2235-2988 (Electronic) Linking ISSN: 22352988 NLM ISO Abbreviation: Front Cell Infect Microbiol Subsets: MEDLINE
    • Publication Information:
      Original Publication: Lausanne : Frontiers Media SA
    • Subject Terms:
    • Abstract:
      Background: Invasive fungal infection (IFI) is one of the most common nosocomial infections. However, data on the epidemiology of IFI and susceptibility to antifungal agents in China are quite limited, and in particular, no current data exist on the microbiological, and clinical characteristics of IFI patients in Northeast China. Objectives: The purpose of this study was to provide a retrospective review of the clinical characteristics, laboratory test results, and risk factor predictions of inpatients diagnosed with IFI. Multivariate regression analysis was used to assess prognostic factors associated with the mortality of these patients. Methods: We retrospectively analyzed the results from 509 patients with IFI extracted from the First Hospital of China Medical University from January 2013 to January 2018. Results: Neutrophil numbers, total bilirubin, length of stay in the ICU, renal failure, use of immunosuppressants within the past 30 days, stomach tube placement and septic shock were risk factors for death from IFI. Recent surgery (within 2 weeks) and drainage tube placement did not increase mortality in these IFI patients. Increased serum levels of PCT (AUC 0.601, 95% CI 0.536-0.665, P = 0.003) and CRP (AUC 0.578, 95% CI 0.512-0.644, P = 0.020) provided effective predictors of 30-day mortality rates. Conclusions: We report for the first time epidemiological data on invasive fungal infections in Northeast China over the past 5 years. Despite the limited available clinical data, these findings will greatly aid clinical health care workers with regard to the identification, prevention, and treatment of IFI in hospitalized patients.
      (Copyright © 2020 Li, Gao, Niu, Wu, Du, Yang, Qi, Chen, Gao, Song and Guan.)
    • References:
      Mol Cell Biol. 2004 May;24(9):3874-84. (PMID: 15082781)
      JAMA. 2016 Oct 18;316(15):1555-1564. (PMID: 27706483)
      Braz J Med Biol Res. 2018;51(7):e6783. (PMID: 29846409)
      Curr Opin Crit Care. 2010 Oct;16(5):445-52. (PMID: 20711075)
      J Antimicrob Chemother. 2013 Dec;68(12):2718-32. (PMID: 23869049)
      BMC Infect Dis. 2017 May 6;17(1):329. (PMID: 28477628)
      Med Mycol. 2014 Feb;52(2):115-22. (PMID: 24626056)
      Gut Microbes. 2013 Sep-Oct;4(5):409-15. (PMID: 23941906)
      Crit Care. 2019 May 28;23(1):190. (PMID: 31138262)
      N Engl J Med. 2016 Feb 25;374(8):794. (PMID: 26933867)
      Crit Care. 2017 Jul 10;21(1):176. (PMID: 28693606)
      J Microbiol Immunol Infect. 2017 Feb;50(1):97-103. (PMID: 25769664)
      Pathog Dis. 2016 Nov;74(8):. (PMID: 27702795)
      Intensive Care Med. 2012 Aug;38(8):1315-25. (PMID: 22752333)
      Clin Microbiol Rev. 2007 Jan;20(1):133-63. (PMID: 17223626)
      Eur J Clin Microbiol Infect Dis. 2018 Sep;37(9):1717-1724. (PMID: 30030692)
      J Antimicrob Chemother. 2016 Aug;71(8):2262-9. (PMID: 27125554)
      Clin Infect Dis. 2013 May;56(9):1284-92. (PMID: 23315320)
      J Heart Lung Transplant. 2003 Mar;22(3):258-66. (PMID: 12633692)
      J Antimicrob Chemother. 2016 Nov;71(suppl 2):ii13-ii22. (PMID: 27880665)
      Clin Chest Med. 2017 Sep;38(3):385-391. (PMID: 28797483)
      Med Mycol. 2015 Sep;53(7):645-55. (PMID: 26162475)
      Infection. 2016 Apr;44(2):205-13. (PMID: 26410297)
      Infect Dis Clin North Am. 2017 Sep;31(3):475-487. (PMID: 28687215)
      Clin Infect Dis. 2005 Nov 1;41(9):1232-9. (PMID: 16206095)
      J Antimicrob Chemother. 2013 Dec;68(12):2890-7. (PMID: 23825380)
      Indian J Crit Care Med. 2016 Nov;20(11):633-639. (PMID: 27994377)
      J Antibiot (Tokyo). 2014 Apr;67(4):311-4. (PMID: 24424346)
      PLoS One. 2014 Jan 27;9(1):e87128. (PMID: 24475243)
      N Engl J Med. 2007 Dec 20;357(25):2601-14. (PMID: 18094380)
      HPB (Oxford). 2012 Feb;14(2):136-41. (PMID: 22221576)
      BMC Infect Dis. 2005 Apr 07;5:22. (PMID: 15813977)
      Pediatr Infect Dis J. 2010 Sep;29(9):816-21. (PMID: 20616763)
      Int J Infect Dis. 2016 Nov;52:49-54. (PMID: 27663909)
      Int J Infect Dis. 2010 Nov;14(11):e954-66. (PMID: 20797887)
      Future Microbiol. 2016 Oct;11:1461-1477. (PMID: 27750452)
      Infect Drug Resist. 2017 Feb 02;10:35-41. (PMID: 28203095)
    • Contributed Indexing:
      Keywords: China; bacteremia; epidemic; invasive fungal infection; single center
    • Accession Number:
      0 (Antifungal Agents)
    • Publication Date:
      Date Created: 20201116 Date Completed: 20210617 Latest Revision: 20210617
    • Publication Date:
      20240829
    • Accession Number:
      PMC7642834
    • Accession Number:
      10.3389/fcimb.2020.553648
    • Accession Number:
      33194796